This clinical trial is focused on studying a type of blood cancer called Chronic Lymphocytic Leukemia (CLL) and a similar condition known as Small Lymphocytic Lymphoma (SLL). The study is specifically for elderly patients over 70 years old who have not received treatment for these conditions before. The treatment being investigated is a medication called Acalabrutinib, which is available in two forms: film-coated tablets and hard capsules. Acalabrutinib is a chemical substance that works by targeting specific proteins in cancer cells to stop their growth.
The purpose of this study is to understand if stopping and then restarting Acalabrutinib affects the progression of the disease in frail patients. Participants will take Acalabrutinib for a period, then stop the medication, and later restart it. The study will observe how the disease progresses during this time and whether the treatment helps in maintaining the health of the patients. The trial will also look at the overall survival of patients and their quality of life using a questionnaire.
Throughout the study, the health of the participants will be closely monitored to ensure their safety and to gather information on how effective the treatment is. The trial aims to provide insights into whether this approach can be beneficial for patients with CLL or SLL, especially those who are older and have not been treated before. The study is expected to continue until 2028, allowing researchers to collect comprehensive data on the treatment’s impact over time.
France 
